Evaluation of 12-and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors
Evaluation of 12-and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors
复制标题
DOI：
10.2460/ajvr.71.11.1354
复制
发表时间：
2010-11-01
影响因子：
1
通讯作者：
Hermine, Olivier
中科院分区：
文献类型：
--
作者：
Hahn, Kevin A.;Legendre, Alfred M.;Hermine, Olivier
动物-132只患有不可切除的2级或3级MCT的狗。程序-狗接受马赛替尼（12.5mg/kg/d，PO; n = 106）或安慰剂（26）。6个月后，治疗延长，每3个月进行一次肿瘤评估，直至检测到疾病进展。研究终点为肿瘤反应和总生存率及时间。结果-在患有不可切除MCT的犬中，与安慰剂组相比，马赛替尼显著提高了存活率，95只犬中有59只存活，12个月时分别有25只犬中的33只（62.1%）和9只（36.0%）存活，24个月时分别有83只犬中的33只（39.8%）和20只犬中的3只（15.0%）存活。中位总生存时间分别为617天和322天。6个月的肿瘤控制对24个月生存率有很高的预测价值，具有高特异性（88%）和敏感性（76%），而短期肿瘤缓解（6周内）的预测价值较差。在用马赛替尼治疗的67只患有不可切除的MCT的狗中的6只（9.0%）中观察到24个月时的完全反应。结论和临床相关性马赛替尼显著增加患有不可切除的MCT的狗在12和24个月时的存活率。在6个月时控制疾病，但在6周时不是最佳反应，预测用马赛替尼治疗的狗的长期存活，这表明短期反应可能与评估酪氨酸激酶抑制剂治疗MCT的临床功效无关。(Am J Vet Res 2010;71：1354-1361）
Objective-To evaluate the effectiveness of masitinib for the treatment of nonresectable mast cell tumors (MCTs) in dogs at 12 and 24 months after onset of treatment.Animals-132 dogs with nonresectable grade 2 or 3 MCTs.Procedures-Dogs received masitinib (12.5 mg/kg/d, PO; n = 106) or a placebo (26). After 6 months, treatment was extended with tumor assessments at 3-month intervals until detection of disease progression. Endpoints were tumor response and overall survival rate and time.Results-In dogs with nonresectable MCTs, masitinib significantly improved survival rate, compared with results for the placebo, with 59 of 95 (62.1%) and 9 of 25 (36.0%) dogs alive at 12 months and 33 of 83 (39.8%) and 3 of 20 (15.0%) dogs alive at 24 months, respectively. Median overall survival time was 617 and 322 days, respectively. Tumor control at 6 months had a high predictive value for 24-month survival, with high specificity (88%) and sensitivity (76%), whereas short-term tumor response (within 6 weeks) had a poor predictive value. Complete responses at 24 months were observed in 6 of 67 (9.0%) dogs with nonresectable MCTs treated with masitinib.Conclusions and Clinical Relevance-Masitinib significantly increased survival rates at 12 and 24 months in dogs with nonresectable MCTs. Control of disease at 6 months, but not best response at 6 weeks, was predictive of long-term survival in dogs treated with masitinib, which suggested that short-term response may be irrelevant for assessing clinical efficacy of tyrosine kinase inhibitors for treatment of MCTs. (Am J Vet Res 2010;71:1354-1361)